GlassScriptPhysician profile
Marie Serfis
NPI 1457130601
$2,297.99
in general payments reported to CMS, 2019-2025
30 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.29 · 2024: $889 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.14 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $460.93 | 2024-2025 | |
| Pfizer INC. | $415.77 | 2024-2025 | |
| Novo Nordisk INC | $283.87 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $217.58 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $117.12 | 2024-2025 | Evenity, Repatha, Otezla |
| Exact Sciences Corporation | $71.26 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.73 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $52.91 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $46.32 | 2024-2025 | Airsupra |
| Esperion Therapeutics, INC. | $45.95 | 2024-2025 | Nexletol |
| Lundbeck LLC | $41.60 | 2024-2025 | Vyepti |
| Sumitomo Pharma America, INC. | $41.57 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $37.37 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $36.03 | 2024-2025 | Ajovy |
| Edwards Lifesciences Corporation | $34.59 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $34.15 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.52 | 2024-2025 | Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $30.43 | 2024 | Trintellix |
| Glaxosmithkline, LLC. | $30.05 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $24.64 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $21.54 | 2024 | Rexulti |
| Blueprint Medicines Corporation | $21.29 | 2023 | |
| Seqirus USA INC | $21.17 | 2025 | Fluad, Flucelvax |
| Philips North America LLC | $20.66 | 2024 | (Ck6) Holter |
| Ardelyx, INC. | $16.80 | 2024 | Ibsrela |
| Kyowa Kirin, INC. | $15.87 | 2024 | Crysvita |
| Astellas Pharma US INC | $15.81 | 2024 | Veozah |
| Medtronic, INC. | $14.64 | 2025 | Inceptiv |
| Amneal Pharmaceuticals LLC | $13.93 | 2025 | Unithroid |
| Genzyme Corporation | $13.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Serfis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.